(18)F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs

SIMPLE SUMMARY: Epithelial growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the first-line therapy for patients with advanced-stage lung adenocarcinoma with EGFR mutations. However, 17–31% of these patients do not respond to therapy, making early evaluation of treatment response cru...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yu-Erh, Tsai, Ying-Huang, Huang, Yu-Jie, Lung, Jr-Hau, Ho, Kuo-Wei, Yen, Tzu-Chen, Chan, Sheng-Chieh, Chen, Shu-Tian, Tsai, Ming-Feng, Hung, Ming-Szu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945925/
https://www.ncbi.nlm.nih.gov/pubmed/35326662
http://dx.doi.org/10.3390/cancers14061507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945925/
https://www.ncbi.nlm.nih.gov/pubmed/35326662
http://dx.doi.org/10.3390/cancers14061507

Ejemplares similares